Physician profile
Andrew J Mcdevitt
NPI 1487287793
$6,940.29
in general payments reported to CMS, 2019-2025
25 companies · $840 in 2025
The $840 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,003 · 2022: $1,469 · 2023: $1,549 · 2024: $1,080 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.16 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,488.66 | 2021-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $1,029.86 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $977.20 | 2021-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $763.30 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $413.24 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.18 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $295.84 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $254.38 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $218.11 | 2021-2022 | |
| Eisai INC. | $200.03 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $171.08 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.99 | 2022-2025 | |
| Mylan Specialty L.P. | $94.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $87.41 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $62.97 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $60.49 | 2021 | |
| Daiichi Sankyo INC. | $60.38 | 2021-2023 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $58.93 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $53.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.49 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.24 | 2023 | Eliquis |
| Esperion Therapeutics, INC. | $30.19 | 2021 | |
| Exact Sciences Corporation | $17.93 | 2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $13.51 | 2023 | Austedo |
| Biohaven Pharmaceuticals, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcdevitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.